TD Cowen Maintains Rallybio(RLYB.US) With Buy Rating

TD Cowen analyst Ritu Baral maintains $Rallybio(RLYB.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 43.5% and a total average return of 7.4% over the past year.No

moomoo NewsJun 18 07:31 ET · Ratings

JMP Securities Maintains Rallybio(RLYB.US) With Buy Rating, Maintains Target Price $8

JMP Securities analyst Jonathan Wolleben maintains $Rallybio(RLYB.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 0.0% and a

moomoo NewsJun 17 15:31 ET · Ratings

Express News | Rallybio Corp: On Track to Initiate Rlyb212 Phase 2 Dose Confirmation Study in Pregnant Women at Higher Risk for Fnait in 2H 2024

ReutersJun 17 08:06 ET

Express News | Rallybio Corp: Topline Results Suggest Significant Increase in Number of Pregnancies at Higher Risk for Fnait Annually and Rlyb212 Addressable Market

ReutersJun 17 08:05 ET

Express News | Rallybio Announces Results of Epidemiological Analysis Demonstrating Fnait Risk Across Racially and Ethnically Diverse Populations

ReutersJun 17 08:04 ET

12 Health Care Stocks Moving In Thursday's After-Market Session

GainersVenus Concept (NASDAQ:VERO) stock rose 131.0% to $1.43 during Thursday's after-market session. The market value of their outstanding shares is at $9.0 million. Cyclacel Pharmaceuticals (NASDAQ:

BenzingaJun 6 16:31 ET